



May 26, 2021 | virtual

PANELS
(for a list of Participating Companies, see Page 2)

8:00 - 9:00 AM ET

PANEL: Transcatheter Mitral Valve Repair – Assessing current market dynamics

Moderator: Suraj Kalla, Managing Director, Senior Analyst for MedTech, Oppenheimer & Co. Inc.

Comps: ABT, EW, MDT, BSX

Speaker: Dr. Paul Sorajja, Interventional Cardiology Specialist, Minneapolis Heart Institute at Abbott Northwestern Hospital

Dr. Paul Sorajja is an Interventional Cardiology Specialist affiliated with Minneapolis Heart Institute at Abbott Northwestern Hospital. He was previously a professor of medicine at the Mayo Clinic, where he also completed his residency. Dr. Sorajja has authored over 100 publications. Dr. Sorajja is a fellow of the American College of Cardiology, and American Heart Association. His specialties includes: structural heart interventions such as TAVR, paravalvular leak repair, and balloon valvuloplasty amongst others.

Speaker: Dr. Stephan von Bardeleben, Head of the Department for Structural Heart Disease and Interventional Heart Valve Therapy at Mainz University of Medicine

Dr. Stephan von Bardeleben is the head of the Department for Structural Heart Disease and Interventional Heart Valve Therapy at Mainz University of Medicine in Germany. His department is one of the leading worldwide centers in Mitral and Tricuspid valve interventions, and has participated in a number of early clinical trials for these types of treatments. He was the previous president of the group Echocardiography of the German Society of Cardiology. Dr. von Bardeleben is the co-editor-in-chief for the Echocardiography journal, as well as a reviewer for several others.

12:15 - 1:15 PM ET

PANEL: The Expanding Use of Diabetes Devices

Moderator: Steve Lichtman, Managing Director, Senior Analyst for MedTech, Oppenheimer & Co. Inc.

Comps: ABT, DXCM, MDT, MNKD, NMRD, PODD, SENS, TNDM

Speaker: Dr. Tracey McLaughlin, Professor of Medicine, Division of Endocrinology, at the Stanford University School of Medicine

Dr. Tracey McLaughlin is a Professor of Medicine, Division of Endocrinology, at the Stanford University School of Medicine. Dr. McLaughlin conducts clinical research related to obesity, insulin resistance, diabetes, and cardiovascular disease (CVD). She also maintains an active clinic for patients with complicated type 1, type 2, or other forms of diabetes, polycystic ovarian disease, and hypoglycemia. Dr. McLaughlin has over 100 publications in peer-reviewed journals and is founder of the Diabetes Task Force at Stanford Hospital.

Speaker: Kelly Close, Founder, The diatribe Foundation; President, Close Concerns, Inc.

Kelly Close founded Close Concerns in 2002; Kelly and her team write extensively on diabetes, pre-diabetes, obesity, and digital health for Closer Look, a highly-praised subscription news service which keeps researchers and members of industry abreast of scientific breakthroughs and market dynamics. Kelly also is founder of diatribe, an education resource which informs patients and caregivers of the latest products and research in diabetes. Kelly is an associate editor of Clinical Diabetes, a journal focused on diabetes for primary care physicians published quarterly by the ADA. Kelly also chairs The diatribe Foundation, a nonprofit established in 2013 to improve the lives of people with diabetes and pre-diabetes and to advocate for action. Kelly's passion for the field comes from her extensive professional work as well as from her personal experience, having had diabetes for nearly 35 years. Kelly is the author of over 35 peer-reviewed manuscripts as well as "Targeting A Cure for Type 1 Diabetes: How Long Do We Have to Wait?" an award-winning book published by the ADA in 2013.

1:25 - 2:25 PM ET

PANEL: Robotics: Expanding Access, Solving Unmet Needs and Influencing MedTech Manufacturing

Moderator: Louis A. Cannon, MD, Founder SR Mg Director the BioStar Funds, Founder, President, The Cardiac & Vascular Research Center of N. Michigan

Join us for a discussion of how robots are influencing MedTech Manufacturing (FOLDAX), expanding access to care (CORINDUS and Telerobotic), and a discussion on whether there are unmet needs that robotics can solve in healthcare (e.g., Micro Surgical Robotic (MMI)) that humans cannot.



Speaker: Ken Charhut, Executive Chairman FOLDAX, former CEO MindFrame, Founder and former CEO of Compellon

Ken brings more than thirty years of medical device experience to Foldax. Currently, he leads two medical device and technology companies. He is executive chairman of the board of Foldax and chairman of the board for Compellon, a bioinformatics company. Previously, Ken held board and CEO roles at Reshape Medical a private device company which commercialized products to treat obesity that was acquired by EnteroMedics in 2017. He was President and CEO of MindFrame, Inc., which makes devices to treat ischemic strokes. In July 2012, Covidien, the world leader in that market, acquired MindFrame. Earlier, Ken was CEO and President of Orqis Medical, privately funded company in the congestive heart failure space. Ken raised over \$85 million for the company and took it from concept through IDE clinical trials. Prior to Orqis, Ken spent 16 years in general management position with Baxter Healthcare corporation, including President of the Bentley Division and President of New Business Initiatives for the Cardiovascular Surgery Division. He also spent four years in Japan as Managing Director of Baxter Japan Cardiovascular Division. Ken earned his B.S.M.E degree from Cornell University and his M.B.A. from the University of Chicago Booth School of Business and completed the manufacturing management program of General Electric Company.



Speaker: Mark Toland, CEO, MMI MicroSurgical Robotics, former CEO of Corindus Vascular Robotics

Mark Toland is the CEO of MMI SpA. Before joining MMI, Mark served as the President and CEO of Corindus where he transformed the company into the industry leader in vascular robotics with the only approved system for coronary, peripheral and neurovascular indications. The Siemens Healthineers acquisition of Corindus for \$1.1 billion was the fifth largest medical technology acquisition of 2019. Prior to Corindus, Mark served as Senior Vice President of Boston Scientific, where he built the company's global solutions business and led all aspects of the U.S. commercial team's cardiovascular businesses, which represented approximately \$4 billion in revenue. Mark brings over 25 years of medical device experience to MMI. In addition, he serves on the Board of Directors for Cardiologs, a cardiovascular AI company, and Amplitude Vascular Systems, an Intravascular Lithotripsy company. He also serves as a partner and EIR at Biostar Capital, a healthcare focused Venture Capital firm. Mr. Toland holds a Bachelor of Science in Business Administration from the University of Louisville.



Speaker: Ray Turner, MD, Neurosurgeon and Endovascular Surgeon; TeleRobotics Treating Strokes Robotically; access to care imperative

Ray Turner is currently Professor Surgery and an Endovascular Neurosurgeon. He is also Chief Medical Officer for Neurovascular and Robotics at Siemens Healthineers. He was also previously a Professor in the Department of Neurosurgery at the Medical University of South Carolina. He hold a B.S. from Sacred Heart University and a M.D. from Karol Marcinkowski University of Medical Sciences in Poland.



Moderator: Louis A. Cannon, MD, Founder SR Mg Director the BioStar Funds, Founder, President, The Cardiac & Vascular Research Center of N. Michigan

Louis Cannon, MD, a former Judith Volkman Scholar in Residence, is the President of the Cardiac and Vascular Research Center of Northern Michigan. Dr. Cannon has been repeatedly honored as one of "America's Top Interventional Cardiologists". He has authored hundreds of articles for medical publications, and has received medical device patents. He has served on the strategic advisory boards for Fortune 500 companies such as Medtronic, Abbott, Boston Scientific, Johnson and Johnson, and Covidien, as well as pharmaceutical and early developing medical technology companies. Biostar Capital and Dr. Cannon have been active in the robotic space. Dr. Cannon recently served as a Director and Member of the Finance and Audit committees of Corindus Vascular Robotic Systems which was acquired by Siemens Healthineers for over a billion dollars and represented one of the largest med tech deals of the year. BioStar Fund III is an active and early investor in Foldax a revolutionary robotic method to manufacture polymeric valves which will potentially reduce COGS, improve precision and durability of heart valves and provide for a non-animal based solution. In 2020, Foldax was the recipient of the "MedTech Breakthrough Award for CardioVascular Technology" as well as the "Medical Device Engineering Breakthrough Award".



May 26, 2021 | virtual

PARTICIPATING COMPANIES as of 5/18/21

Company	TCKR	MC (\$M)	Description	Comps	Presentation	Management
Anika Therapeutics	ANIK	580.2	Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers meaningful advancements in early intervention orthopedic care, as well as develops minimally invasive products. Anika Therapeutics serves customers worldwide.	SYK, ZBH	Recorded Presentation Available	Cheryl Blanchard, President & CEO
Avinger	AVGR	145.8	Avinger, Inc. manufactures medical devices. The Company offers surgical devices, medical instruments, apparatus, and other equipment. Avinger serves customers in the United States.	ZBH		Jeff Soinski, CEO Mark Weinswig, CFO
Asensus Surgical	ASXC	793.1	Asensus Surgical, Inc. is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery (MIS) through digital laparoscopy category. The Company focuses on augmented intelligence, connectivity, and robotics in laparoscopy, addresses the current clinical, cognitive, and economic shortcomings in surgery.	ISRG, TMDI, MDT, JNU	Recorded Presentation Available	Shameze Rampertab, CFO
Beyond Air	XAIR	120.3	Beyond Air, Inc. operates as a medical device and biopharmaceutical company. The Company focuses on the discovery and development of a nitric oxide formulation and delivery systems to treat various respiratory diseases. Beyond Air serves patients and customers in the United States and Israel.	MNKKQ		Steve Lisi, CEO
Biocartis	BCART	255.0	Biocartis Group NV develops molecular diagnostic testing solutions. The Company offers automated instruments for detection, data analysis, and reporting services. Biocartis Group focuses on clinical practices for the benefit of patients, clinicians, payers, and industry. Biocartis Group serves the pharmaceutical and healthcare industries worldwide.	VCYT		Herman Verreist, CEO Jean-Marc Roelandt, CFO
Bionano Genomics	BNGO	1,698.4	Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents. Bionano Genomics serves customers in the United States.	PACB		TBA
BioSig	BSGM	151.0	BioSig Technologies, Inc. develops medical devices. The Company offers proprietary technology to minimize noise and artifacts from cardiac recordings during electrophysiology studies and ablation. BioSig operates in the United States.	ATRC, BSX, MDT		Ken Londoner, Chairman & CEO
BrainsWay Ltd.	BWAY	157.4	BrainsWay Ltd operates as a commercial stage medical device company. The Company focuses on the development and sale of non-invasive neuromodulation products for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). BrainsWay offers its services worldwide.	TCMD, XENT, STIM, KIDS, SPNE, SIBN, CRY	Recorded Presentation Available	Christopher von Jako, President & CEO
CardioNXT	Private	-	CardioNXT is building a platform of products that enable a better understanding of complex cardiac arrhythmias such as Atrial Fibrillation, and furthermore deliver targeted therapy to affected areas within the heart.	ATRC, BSX, MDT, IRTC	Recorded Presentation Available	Jerome Edwards, CEO
Castle Biosciences	CSTL	1,479.2	Castle Biosciences, Inc. provides healthcare imaging services. The Company offers diagnostic and prognostic testing solutions for cancers, as well as research and development activities. Castle Biosciences serves customers in the United States.	DMTK	Recorded Presentation Available	Derek Moeltzold, President & CEO; Frank
Conformis	CFMS	176.7	Conformis, Inc. develops and manufactures knee implants. The Company offers femoral and tibial knee implants for the treatment of osteoarthritis and joint damages. Conformis markets its products and services to orthopedic surgeons and orthopedic surgical centers in the United States.	ATRC, CNMD, NUVA, CSII, OFIX	Recorded Presentation Available	TBA
CytoSorbents	CTSO	380.7	CytoSorbents Corp. is involved in the research, development and commercialization of medical devices with its platform blood purification technology. The Company focuses on developing this technology for multiple applications in the medical field for the treatment of acute and chronic health complications associated with blood toxicity.	BAX, FMS, DVA, OM	Recorded Presentation Available	Dr. Philip Chan, CEO Kathy Bloch, CFO
DexCom, Inc.	DXCM	35,603.2	DexCom Inc. operates as a medical device company focused on the design and development of continuous glucose monitoring systems for people with diabetes. The Company has developed a small implantable device that continuously measures glucose levels in subcutaneous tissue just under the skin and a small external receiver to which the sensor transmits glucose levels at specified intervals.	ABMD, ALGN, NVRO, GKOS, ISRG, EW, PEN, POOD, INDM, INSP, SWAV, STAA		Jerome Sylvain, CFO
Fluidigm	FLDM	351.1	Fluidigm Corporation develops, manufactures, and markets proprietary integrated fluidic circuit systems. The Company commercialized IFC systems for a wide range of life science applications including a system for gene expression analysis, genotyping, and digital PCR, and a system for protein crystallization.	NSTG	Recorded Presentation Available	Chris Linthwaite, President & CEO Vikram Jag, CFO
Fulgent	FLGT	2,800.4	Fulgent Genetics, Inc. operates as a technology company. The Company develops a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools, and integrated laboratory processes. Fulgent Genetics offers genetic testing to provide physicians with clinically diagnostic information.	INVTA, MYGN, QDEL		Paul Kim, CFO Brandon Perthuis, COO
iCad	ICAD	495.9	iCAD, Inc. provides advanced breast cancer detection and radiation therapy solutions. The Company offers advanced hardware and software, as well as management services designed to support cancer detection and radiation therapy treatments. iCAD serves customers in the United States.	ISO, HOLX, FLGT	Recorded Presentation Available	TBA
Isray Inc.	ISR	155.3	IsRay, Inc., through its subsidiary, produces a brachytherapy seed, used to treat prostate and other cancers. The Company's seed delivers more than 90 percent to its total radiation dose in less the 33 iCAD days, reducing the incidence of common brachytherapy side effects.		Recorded Presentation Available	Lori Woods, CEO Jonathan Hunt, CFO
Koya Medical	Private	-	Koya Medical received FDA-clearance for the Dayspring system, a prescription only mobile active compression system for the treatment of lymphedema and venous insufficiency. Dayspring is the first digitally connected system with an FDA cleared label enabling patient mobility during use	TCMD		Andy Daraiswamy, President & CEO
LENSAR	LSNR	76.1	LENSAR, Inc. develops laser technologies. The Company provides autoprocedure laser and proprietary 3-D imaging, measurement, and guidance system for refractive cataract surgery. LENSAR serves the healthcare industries throughout the United States.	AERI, KALA	Recorded Presentation Available	TBA
LumiThera	Private	-	LumiThera is a medical device company at the forefront in the development of photobiomodulation (PBM) treatment protocols for patients with dry AMD.	AERI, KALA		Clark Tedford, President & CEO



May 26, 2021 | virtual

Myomo	MYO	58.6	Myomo, Inc. operates as a medical robotics company. The Company offers expanded mobility for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets arm braces to restore function in the paralyzed and weakened arms and hands of individuals that have suffered a stroke, spinal cord, and nerve injury.	CRY, BWAY, STIM, KIDS, SIBN, SPNE	Recorded Presentation Available	Paul Gudonis, CEO David Henry, CFO
NeuroOne Medical Tech.	NMTC	104.4	NeuroOne Medical Technologies Corporation develops film electrode technology. The Company provides diagnosis through EEG recording, spinal cord stimulation, brain stimulation and ablation solutions for patients with neurological disorders.	MDT, ZBH, SYK, PEN, SILK	Recorded Presentation Available	Dave Rosa, CEO Ron McClurg, CFO
Oncocyte	OCX	493.5	Oncocyte Corporation operates as a molecular diagnostics company. The Company offers actionable answers at decision points across the cancer care continuum, as well as focuses on improving patient outcomes by accelerating and optimizing diagnosis and treatment. Oncocyte serves clients in the United States.	BSDX	Recorded Presentation Available	Ronnie Andrews, CEO Mitch Levine, CFO
Owlet	Private	-	Owlet has built a connected and accessible nursery ecosystem that brings technology and vital data to modern parenting. The Company's bestselling flagship product, the Owlet Smart Sock baby monitor, uses proprietary and innovative pulse-oximetry technology to track a baby's heart rate, oxygen levels and sleep patterns to provide parents with invaluable peace of mind.	SUMR	TBA	TBA
Personalis	PSNL	1,081.6	Personalis, Inc. provides genomic sequencing and analytics solutions. The Company supports the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Personalis serves customers worldwide.	GH, NVTA, EXAS	Recorded Presentation Available	John West, CEO Aaron Tachibana, CFO
STAAR Surgical Company	STAA	4,962.9	STAAR Surgical Company develops, manufactures, and markets high margin visual implants that improve a patient's quality of vision. The Company manufactures implantable contact lenses to treat refractive disorders such as myopia. STAAR also manufactures products for cataract surgery and glaucoma surgery.	IRTC, ATRC, AMNX, INVRO, INMD, CRY, SIBN, SILK, XENT, TNDM, KIDS	Recorded Presentation Available	Patrick Williams, CFO
Strata Skin	SSKN	57.5	Strata Skin Sciences, Inc. is a medical technology company. The Company designs and develops non-invasive point-of-care instruments to assist in the diagnosis of melanoma. Strata Skin Sciences serves the dermatologists and patients in the United States.	SOLY, VERO	Recorded Presentation Available	Bob Moccia, CEO
Tandem Diabetes Care	TNDM	5,379.2	Tandem Diabetes Care, Inc. produces medical devices. The Company designs, develops, and commercializes products for people with insulin-dependent diabetes. Tandem Diabetes Care offers its products to the medical industries in the United States.	DXCM, PODO	Recorded Presentation Available	John Sheridan, President & CEO Susan Morrison, EVP & CAO
Titan Medical	TMDI	189.5	Titan Medical Inc. is developing a 3-armed robotic surgical system to permit surgeons to remotely manipulate surgical instruments.	ASXC, ISRG	Recorded Presentation Available	David McNally, President & CEO Monique Delorme, CFO
ViewRay	VRAY	775.1	ViewRay Inc. develops radiation therapy technology for the treatment of cancer. The Company offers radiation therapy systems that images and treats cancer patients simultaneously. ViewRay serves customers worldwide.	ARAY, EKTAY, VAR	TBA	TBA
Zimmer Biomet	ZBH	33,893.2	Zimmer Biomet Holdings, Inc. designs, develops, manufactures, and markets medical equipment. The Company offers orthopedic, dental, and spinal reconstructive implants, as well as bone cement and related surgical products. Zimmer Biomet Holdings serves patients worldwide.	SYK		Keri Mattox, SVP IR Ezgi Yagci, IR Manager

Conferences are only open to established institutional clients of Oppenheimer & Co. Inc. For more information, please contact your Oppenheimer & Co. Inc. institutional sales representative.